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Abstract
Aim To determine if a regimen with prandial + basal insulin compared with basal insulin attenuates post-meal inﬂammatory
and glycative biomarkers in patients with Type 2 diabetes.
Methods This test-meal sub-study in the USA is from a previously reported clinical trial comparing the effect on glycaemic
controlof24 weeksofthrice-dailypre-mealinsulinlispromix 50(50%insulinlispro,50%insulinlisproprotaminesuspension)
or bedtime insulin glargine, both plus metformin. In the sub-study, glucose, insulin, triglycerides, high-sensitivity C-reactive
protein, tumour necrosis factor a, interleukin-6, methylglyoxal and 3-deoxyglucosone were measured during the post-meal
periodofamixed-mealbreakfastattheﬁnalvisit.Prandial + basal(n = 25)andbasal(n = 21)insulinwereadministeredatthe
same times as during the previous 24 weeks.
Results Post-meal, the prandial + basal insulin group had signiﬁcantly higher insulin, lower glucose and triglycerides, as well
as lower high-sensitivity C-reactive protein, tumour necrosis factor a and interleukin-6, than the basal insulin group. Glucose
incrementalareaundertheconcentrationcurvesigniﬁcantlycorrelatedwithhigh-sensitivityC-reactiveprotein,tumournecrosis
factor a, interleukin-6, methylglyoxal and 3-deoxyglucosone incremental area under the concentration curve. Insulin
incrementalareaundertheconcentrationcurvecorrelatedinverselywithhigh-sensitivityC-reactiveproteinandtumournecrosis
factor a incremental area under the concentration curve. However, after adjusting for glucose incremental area under the
concentrationcurve,theseinversecorrelationswerenolongersigniﬁcant.Triglycerideincrementalareaundertheconcentration
curve was not correlated with any biomarker incremental area under the concentration curve.
Conclusions Controlling post-mealhyperglycaemia with prandial + basal insulin in patients with Type 2 diabetes attenuates
meal-induced increases in high-sensitivity C-reactive protein, interleukin-6 and tumour necrosis factor a compared with basal
insulin. The rise in post-meal glucose, but not triglycerides, signiﬁcantly correlated with the rise in post-meal inﬂammatory and
glycative biomarkers.
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Introduction
Post-meal hyperglycaemia is considered a risk factor for
cardiovascular disease in patients with Type 2 diabetes [1].
Post-mealincreasesinglucoseandtriglyceridescanbeassociated
with inﬂammation, oxidative stress, glycative stress and
endothelial dysfunction [2–6]. Treatments that target post-meal
hyperglycaemia are recommended [1], but few studies have
investigated the impact of therapeutic interventions on the meal-
induced inﬂammatory response in Type 2 diabetes. Decreasing
post-meal hyperglycaemia with oral glucose-lowering agents
such as mitiglinide and repaglinide can attenuate meal-induced
increases in several inﬂammatory cytokines [7,8] and can
decrease carotid intima-media thickening in Type 2 diabetes
[8]. To the best of our knowledge, however, the effect of
controlling post-meal hyperglycaemia with prandial + basal
insulin on meal-induced high-sensitivity C-reactive protein
(hsCRP), tumour necrosis factor a (TNF-a) and interleukin-6
in patients with Type 2 diabetes has not been reported.
Basal insulin is widely recommended for patients with Type 2
diabetes who cannot achieve glycaemic goals with oral glucose-
lowering medications alone [9]. Because this regimen may fail to
control post-meal hyperglycaemia, an alternate approach is to
useprandial + basalinsulinasamixtureofshort-orrapid-acting
and basal insulin in various ratios [10]. In individuals without
diabetes, approximately 50% of daily insulin secretion is basal,
while the remainder is prandial [11]. Therefore, a 50⁄50 mix of
prandial + basal insulin can approximate normal insulin
secretion and we recently showed that it can be used to control
both pre- and post-meal hyperglycaemia in patients with Type 2
diabetes [12].
Wenowreportasub-studyoftheparentstudy[12],whereour
current goal is to simultaneously measure the changes in plasma
hsCRP,TNF-aandinterleukin-6afteramixed-mealbreakfastin
patientswithType 2diabetesandrelatethesechangestothoseof
post-meal glucose, insulin and triglycerides. We postulated that
controlling post-meal hyperglycaemia with a prandial + basal
insulin regimen can attenuate meal-induced increases of these
inﬂammatory cytokines. Because post-meal inﬂammation is
potentially inﬂuenced by glycative stress [6], we also studied the
concomitant changes in the alpha-dicarbonyls, methylglyoxal
and 3-deoxyglucosone, in the post-meal period.
Patients and methods
Parent study
For logistical reasons, this test-meal sub-study was carried out in
the cohort of patients enrolled by clinics in the USA who
participated in the parent study, a multi-country, randomized,
open-label, parallel-group, 24-week clinical trial conducted
in seven countries, comparing the two insulin regimens on
long-term efﬁcacy and safety in patients with Type 2 diabetes.
Fifty-six of the 96 patients from US clinics participated in this
sub-study. The study was conducted according to the guidelines
from the Declaration of Helsinki with approval from a local
ethicalreviewboard.Allpatientsgavewritteninformedconsent.
The entry criteria and results of the parent study have been
previously reported [12]. Brieﬂy, patients with Type 2 diabetes
[ages 35–75 years; HbA1c 48–97 mmol⁄mol (6.5–11%)] using
oral glucose-lowering medication(s) alone and⁄or with once- or
twice-dailyinsulinwererecruited.Allpatientswerechangedtoa
regimen containing insulin lispro mix 25 (25% insulin lispro,
75% insulin lispro protamine suspension; LM25; Eli Lilly and
Company, Indianapolis, IN, USA) subcutaneously before
breakfast and evening meal. This was to ensure that insulin-
naı ¨ve patients would accept insulin therapy and that all patients
were on the same insulin regimen when randomized. Metformin
wastakenorallytwicedailyandtitratedtoamaximallytolerated
daily dose of 1000 to 2000 mg.
After 6 weeks of this regimen, patients were randomized to
one of two groups: to receive insulin lispro mix 50 (50% insulin
lispro,50%insulinlisproprotaminesuspension;LM50;EliLilly
and Company) subcutaneously thrice daily before meals
(prandial + basal group) or insulin glargine (Lantus
 ; Sanoﬁ-
Aventis, Paris, France) subcutaneously once daily at bedtime
(basal group). Metformin was continued unchanged in both
regimens. Both insulins were adjusted to achieve a target fasting
blood glucose level < 6.7 mmol⁄l (120 mg⁄dl). In addition,
patients in the prandial + basal group targeted a 2-h post-meal
bloodglucoselevel< 8.0 mmol⁄l(144 mg⁄dl).Thediet,exercise
and concomitant medications plan was not altered during the
study.
Test-meal study
To assess the meal-induced responses of the biomarkers at
baseline and ensure that the two groups had similar post-meal
responses, test meal 1 was given at the end of the lead-in period
(2–10 daysbeforerandomization).Aftercontinuingthespeciﬁed
insulin regimens for 24 weeks, test meal 2 was conducted to test
the study hypothesis.
The standardized test-meal breakfast consisted of a standard
commercial breakfast [one bacon, egg and cheese biscuit, one
hash brown patty and 8 oz (237 ml) of orange juice], containing
39 g fat, 78 g carbohydrate, 24 g protein and 750 kCal. The
nightbeforetestmeal 1,patientsatetheirusualeveningmealand
fasted overnight.Allpatientstook metformin30 min beforeand
injected LM25 15 min before breakfast. The night before test
meal 2, patients ate their usual evening meal and fasted
overnight. All patients took metformin 30 min before the test
meal. Patients treated with insulin glargine injected it at bedtime
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15 min before breakfast,as they had been doing forthe previous
24 weeks. The lunchtime dose of LM50 was omitted on the
study day. After the test-meal breakfast, patients were placed
under observation and were not allowed to eat for the next 8 h,
but had free access to water.
Blood samples were collected 5 min before the test meal (0 h)
and at 1, 2, 3, 4, 6 and 8 h after to measure the levels and timing
of post-meal responses. Levels of plasma glucose, insulin,
triglycerides, chylomicron triglycerides, hsCRP, TNF-a and
interleukin-6 were measured at each time point. Methylglyoxal
and 3-deoxyglucosone were measured at 0, 1, 2 and 3 h as
previously reported [6,14]. Specimens were shipped to a central
laboratory and then to specialized laboratories for analysis as
required.
HbA1c was measured using high-performance liquid
chromatography (Variant; Bio-Rad Laboratories, Munich,
Germany) at Covance Central Laboratory (Indianapolis, IN,
USA). Glucose was determined using a hexokinase method
(Roche Modular Analyser; Roche, Indianapolis, IN, USA).
Insulin was measured with a micro-particle enzyme
immunoassay (IMX Insulin reagent pack; Abbott Laboratories,
Abbott Park, IL, USA). Immunonephelometry with the hsCRP
reagentfromDadeBehringInc.,(Newark,DE,USA)wasusedto
measure hsCRP. Commercially available ELISA kits (Bender
MedSystems Diagnostics GmbH, Vienna, Austria) were used to
assay interleukin-6 and TNF-a [13]. Methylglyoxal and
3-deoxyglucosone were assayed as previously described [6,14].
Plasma and chylomicron triglyceride levels were determined by
enzymatic methods with a Beckman Synchron CX7 chemistry
analyser (Beckman Coulter Inc., Brea, CA, USA). Chylomicron
fractions (Sf > 400) were isolated using a two-step
ultracentrifugation as previously described [15].
Study outcomes
The outcomes were comparisons between treatment groups for
the plasma glucose, insulin, triglyceride, chylomicron
triglyceride, hsCRP, TNF-a, interleukin-6, methylglyoxal and
3-deoxyglucosone concentrations at each time point. Post-meal
total area under the concentration curve (AUC) and incremental
AUCofeachbiomarkerduringthetestmealwerealsocompared.
The incremental AUC measured the integrated excursion during
the post-meal period by subtracting the fasting value from each
parameter value at the designated time during the sampling
period.
Statistical analysis
Based on a previous report that post-meal triglyceride change is
associated with changes in interleukin-6 and TNF-a [4], the
power calculation for the test-meal sub-study was based on the
AUC for chylomicron triglycerides. The study required 48
patients, 24 in each treatment group, to allow detection of a
9.6% between-treatment difference in the change from baseline
AUC, tested using a two-sided test at a signiﬁcance level of
0.05 with 90% power.
Analyses were performed on data from those patients who
completed both test meals: one before randomization and the
other after they had been on their study insulin regimen for
24 weeks. Patient characteristics and demographic variables
weresummarizedbytreatmentgroupandcomparedusingatwo-
sample t-test for the numeric measurements and a v
2-square test
for the categorical measurements. Statistical analyses for total
plasma and chylomicron triglycerides were performed using a
two-sample t-test if the normality test passed. The Mann–
Whitney rank sum test was used if the normality test failed
(SigmaStat; Systat Software Inc., Chicago, IL, USA). All other
analyses were conducted using SAS version 8 (SAS Institute Inc.,
Cary, NC, USA). No adjustments for missing data were
performed except for the last-observation-carried-forward. An
analysis of covariance model was used to compare treatment
differences. The test-meal fasting analysis included the
corresponding fasting value at the test meal before
randomization as a covariate. For the total and incremental
AUC analysis, the corresponding test-meal baseline value was
used as a covariate and treatment was considered as ﬁxed effect.
The incremental AUC of the patients who had both test meals
was analysed for statistically signiﬁcant associations with the
variables. Multiple linear regression models were applied to
assesstheindependenteffectofpost-mealplasmaglucose,insulin
or triglycerides (the independent variables) on hsCRP, TNF-a,
interleukin-6, methylglyoxal and 3-deoxyglucosone. Statistical
adjustmentswere made forfastingplasmaglucose orinsulin and
HbA1c, age, gender and BMI covariates. Partial correlation
analysis was performed to explore the strength and direction of
theassociationbetweenplasmaglucose,insulinandtriglycerides
with hsCRP, TNF-a, interleukin-6, methylglyoxal and
3-deoxyglucosone while adjusting for fasting plasma glucose or
insulin and HbA1c, age, gender and BMI covariates.
Results
Patient baseline characteristics and disposition
Fifty-six patients completed test meal 1 at the end of the lead-in
period before randomization. Ten patients discontinued the
study before test meal 2 at 24 weeks: four prandial + basal
patients (two because of protocol violation, one because of an
adverse event and one because of patient decision) and six basal
patients (two because of perceived lack of efﬁcacy, two because
ofmoveor loss ofcontact,one because ofprotocol violation and
one because of patient decision). Among those completing both
testmeals,25patientswereintheprandial + basalgroupand21
patients were in the basal group. Analysis included data from
these 46 patients.
Baseline patient characteristics were similar in both treatment
groups, except for younger age in the prandial + basal group
(55.1 vs. 59.5 mean years, P = 0.04) (Table 1). In this sub-
study, 10 (40%) of the 25 patients taking LM50 switched from
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parent study, 53 (33.8%) of the 157 patients taking LM50
switched their pre-evening meal injection to LM25 [12]. There
were no differences in baseline demographics (age, gender,
ethnicity) between the 40 US patients who did not participate in
this sub-study and the 46 who participated in both test meals.
Test meal 1 at end of lead-in period
There were no signiﬁcant differences between the two groups at
this test meal with respect to mean plasma concentrations for
plasma glucose, insulin, triglycerides, chylomicron triglycerides,
hsCRP, TNF-a, interleukin-6, methylglyoxal and3-deoxygluco-
sone. There were no signiﬁcant differences between groups in
post-meal total AUC or incremental AUC for any of the
biomarkers. Thus, both groups, while on the same insulin
regimen before randomization, had similar responses to the
mixed-meal breakfast.
Test meal 2 after 24 weeks of treatment
We compared the concentration of each biomarker at each time
point and its incremental AUC of the entire post-meal period
between the prandial + basal and basal groups.
Plasma glucose and insulin
Theprandial + basalgrouphadsigniﬁcantlyhighermeanfasting
plasma glucose, but signiﬁcantly lower plasma glucose at 3 and
4 hafterthe meal(Fig. 1a).Theprandial + basalgroup alsohad
signiﬁcantly lower mean post-meal plasma glucose total AUC
and incremental AUC (Fig. 1a and Table 2).
The prandial + basal group had signiﬁcantly higher mean
plasma insulin at 1 and 2 h and signiﬁcantly higher mean
post-meal plasma insulin total and incremental AUC (Fig. 1b
and Table 2).
Plasma and chylomicron triglycerides
Theprandial + basalgrouphadsigniﬁcantlylowermeanplasma
triglyceride concentrations at 2 and 3 h after the meal (Fig. 1c)
and signiﬁcantly lower chylomicron triglycerides at 1 and 3 h
(Fig. 1d).However,therewerenosigniﬁcantdifferencesbetween
groups in post-meal total or incremental AUC for plasma or
chylomicron triglyceride (Fig. 1c, d and Table 2).
Markers of inﬂammation
Theprandial + basalgrouphadsigniﬁcantlylowerplasmahsCRP
andTNF-aconcentrationat3and4 h(Fig. 1e,f)andinterleukin-
6 at 3, 4 and 6 h after the meal (Fig. 1g). The prandial + basal
group also had signiﬁcantly lower total and incremental AUC
for each of these markers (Fig. 1e, f, g and Table 2).
Methylglyoxal and 3-deoxyglucasone
Althoughtheytrendedlowerintheprandial + basalgroup,there
werenosigniﬁcantdifferencesbetweengroupsinplasmalevelsof
these biomarkers at any time point or for total or incremental
AUC after the meal (Fig. 1h, i and Table 2)
Regression analysis and correlation analysis for meal-induced
biomarker changes (Table 3)
Glucose
The post-meal incremental AUC for glucose was signiﬁcantly
associated with post-meal incremental AUC for hsCRP, TNF-a,
interleukin-6, methylglyoxal and 3-deoxyglucosone. It was not
associatedwiththeincrementalAUCforinsulinandtriglycerides
(Table 3).
Insulin
The post-meal incremental AUC for insulin was signiﬁcantly
inversely associated with the post-meal incremental AUC for
hsCRP and TNF-a(Table 3). However, this relationship was no
longer seen after adjusting for the post-meal glucose incremental
AUC by multivariate analysis.
Triglycerides
The incremental AUC for triglycerides was not signiﬁcantly
associated with the respective post-meal incremental AUC for
glucose, insulin or any of the biomarkers (data not shown).
Discussion
The thrice-daily pre-meal prandial + basal regimen resulted in
higher plasma insulin, lower plasma glucose as well as lower
meal-induced increases in hsCRP, interleukin-6 and TNF-a
Table 1 Baseline characteristics: patients who completed both test meals*
Characteristic
Prandial + basal 
n =2 5
Basal 
n =2 1 P-value
Age, years 55.1 (7.5) 59.5 (6.9) 0.04
Male gender, n (%) 15 (60.0) 15 (71.4) 0.42
Ethnicity, %
White 56 52
0.41
African descent 12 24
East or south-east
Asian
05
West Asian 8 0
Hispanic 24 19
Weight, kg 101.3 (25.2) 95.7 (21.2) 0.43
BMI, kg⁄m
2 35.1 (7.7) 32.1 (6.8) 0.18
HbA1c, mmol⁄mol 56 (16) 55 (16) 0.42
HbA1c, % 7.3 (0.7) 7.2 (0.7)
Duration of disease,
years
11.1 (5.6) 13.4 (7.1) 0.23
Daily insulin injections before study, %
03 6 3 3
0.96
11 6 1 9
24 8 4 8
*Represents data collected at randomization (parent study).
Data are mean (standard deviation) unless otherwise indicated.
 Insulin lispro mix 50 plus metformin group.
 Insulin glargine plus metformin group.
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basal insulin regimen. There were also signiﬁcant decreases of
incremental AUC of inﬂammatory biomarkers (hsCRP,
interleukin-6, TNF-a) associated with the incremental AUC of
glucose.Thestrongcorrelationsbetweenattenuationoftheacute
rise in post-meal glucose andinﬂammatory markers suggest that
glucose may be a factor in their release. This is the ﬁrst study to
show that controlling post-meal hyperglycaemia with a
(a) (b)
(c)
(e)
(g)
(d)
(f)
(h) (i)
FIGURE 1 Plasmalevelsofglucose,insulin,TG(plasma⁄chylomicron),hsCRP,TNF-a,interleukin-6,methylglyoxaland3-deoxyglucosoneaftertestmeal 2.
Priortothetestmeal,patientsweretreatedfor24 weekswithinsulinlispromix 50plusmetformin(blackbarwithdashedtrendline,n = 25)orinsulinglargine
(white bar with solid trend line, n = 21) plus metformin. Results are the mean  standard error of values measured before (0 h) and after the test meal.
ComparisonswerebetweentreatmentsateachtimepointandbetweentreatmentsfortotalAUC.*P < 0.05, P < 0.01, P < 0.001,§P < 0.0001.AUC,area
under the concentration curve; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; TG, triglyceride; TNF-a, tumour necrosis factor alpha.
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attenuatethemeal-inducedincreasesinhsCRP,interleukin-6and
TNF-a in patients with Type 2 diabetes on metformin.
Previous studies on post-meal changes in inﬂammation in
patients with Type 2 diabetes showed varied results. For
example, a high-fat breakfast increased post-meal plasma
interleukin-6 and TNF-a [4], whereas a mixed meal decreased
interleukin-6 and TNF- a in another study [5]. A commercial
meal equivalent meal increased post-meal hsCRP, but not
interleukin-6 [16] and was partially conﬁrmed by a report that
a high-fat and high-glucose meal increased plasma interleukin-6
and hsCRP [7]. Two previous studies on the relationships
between the meal-induced changes in inﬂammatory markers
relative to plasma triglycerides and glucose have also shown
mixed results in patients with Type 2 diabetes. Nappo et al.
showed a signiﬁcant relationship between post-meal changes in
triglycerides and TNF- a⁄interleukin-6 and between post-meal
changes in glucose and interleukin-6 [4], while Carroll and
Schade found no such correlations [16].
Hyperglycaemia has previously been shown to be a major
initiatorofglycative(dicarbonyl)stress[6,14]and thesigniﬁcant
relationship of methylglyoxal and 3-deoxyglucosone with post-
meal glucose in this study conﬁrms this relationship. Cause-and-
effect relationships have also been shown to exist between
inﬂammation and glycative stress [17,18], suggesting that the
elevation of methylglyoxal and 3-deoxyglucosone seen in this
study could initiate inﬂammation in the post-meal state. In the
current study, however, we observed lower, but not statistically
signiﬁcant, methylglyoxal and 3-deoxyglucosone incremental
AUC group differences in the prandial + basal group relative to
Table 2 Comparison between the two insulin treatment groups of post-meal incrementalarea under the curve (AUC) of various biomarkers in test meal 2 at
week 24 after randomization*
Biomarker Prandial + basal  (n = 25) Basal  (n = 21) P-value
Glucose (mmol⁄l)Æmin 323.8 (77.1) 902.8 (98.6) < 0.001
Insulin (pmol⁄l)Æmin§ 46 638 (6813.1) 21 418 (5415.5) < 0.01
TG (mg⁄dl)Æmin 23 962 (2661.8) 25 975 (3074.6) 0.46
CTG (mg⁄dl)Æmin 15 387 (1845.5) 14 414 (2141.3) 0.99
hsCRP (ng⁄ml)Æmin 75 599 (38 756.2) 377 947 (70 693.6) < 0.001
TNF-a (pg⁄ml)Æmin 874.1 (235.8) 2150.1 (435.3) < 0.01
IL-6 (pg⁄ml)Æmin 59.0 (21.3) 138.3 (33.8) < 0.01
3-DG (nmol⁄l)Æmin 1014 (277.2) 1597 (260.9) 0.14
MG (nmol⁄l)Æmin 339.6 (310.4) 1004.3 (410.2) 0.23
3-DG, 3-deoxyglucosone; CTG, chylomicron triglycerides; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; MG, methylgly-
oxal; TG, plasma triglycerides; TNF-a, tumour necrosis factor alpha.
*Data are mean (sem). The P-value calculation included treatment as a ﬁxed effect and baseline value as a covariate.
 Insulin lispro mix 50 plus metformin.
 Insulin glargine plus metformin.
§Insulin incremental AUC: prandial + basal group, n = 24; basal group, n = 20.
Table 3 Regression and correlations for plasma glucose and insulin with biomarkers: incremental area under the curve (AUC)
Variable
PG Incremental AUC Insulin Incremental AUC
Regression
coefﬁcient* P-value*  R 
Regression
coefﬁcient* P-value*  R 
Insulin  )8.23 0.40 )0.14 — — —
TG  )4.16 0.41 0.14 )0.01 0.85 )0.03
hsCRP  419.51 < 0.001 0.68 )3.71 0.01 )0.39
TNF-a  1.46 0.01 0.41 )0.02 0.02 )0.38
IL-6  0.14 < 0.01 0.46 )0.01 0.14 )0.24
3-DG– 3.34 < 0.001 0.62 0.00 0.98 < 0.01
MG– 2.65 0.03 0.34 )0.03 0.08 )0.28
3-DG, 3-deoxyglucosone; AUC, area under the concentration curve; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; MG,
methylglyoxal; PG, plasma glucose; R, partial correlation coefﬁcient; TG, plasma triglycerides; TNF-a, tumour necrosis factor alpha.
*Multiple linear regression approach was applied after adjusting for covariates (fasting PG or insulin; HbA1c, age, gender and BMI).
 Partial correlation controlling for covariates (fasting PG or insulin; HbA1c, age, gender and BMI).
Incremental AUC time period:  0–8 h, –0–3 h.
The P-value applies to both regression and correlation analysis.
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substantial inter-subject data variability and the modest sample
sizeofthestudypopulations.Ourdecision,basedonpriorstudies
[6,14], to measure methylglyoxal and 3-deoxyglucosone only
during the initial 3 h of the post-meal period could also have led
us to miss post-meal changes at later time points, where
signiﬁcant changes were observed for other biomarkers.
Our ﬁnding of an inverse correlation between insulin
incremental AUC and that of three inﬂammatory biomarkers
supportsthehypothesisthatinsulinhasanti-inﬂammatoryeffects
[19,20]. The loss of this effect when the insulin data were
corrected forglucoseeffectby multivariateanalysissuggeststhat
this apparent correlation may be primarily related to glucose
change.Dandonaet al.havereportedthatinsulinhasdirectanti-
inﬂammatoryeffects,but,tothebestofourknowledge,Dandona
et al. [19] did not correlate the magnitude of the change of anti-
inﬂammatory effect with the change in insulin dose or plasma
insulinlevel.Nordidtheycorrectfortheeffectofglucoseintheir
studiesontheanti-inﬂammatoryeffectsofinsulin.Inonestudyof
patients with acute myocardial infarction without diabetes, the
riseininﬂammationwasattenuatedinthegroupreceivinginsulin
infusioncomparedwiththegroupnotreceivinginsulin,although
glucose levels were similar in both groups [21]. Our study differs
from these other studies in the aims and designs of studies, study
subjects (subjects with Type 2 diabetes vs. subjects without
diabetes), meal challenge (mixed meal vs. oral glucose [19],
except for one study using mixed meal [20]) and use of constant
insulin infusion vs. bolus insulin analogue.
Although we observed a modest improvement in post-meal
plasma and chylomicron triglyceride concentrations with pre-
meal prandial + basal over the ﬁrst 3 h of the post-meal period,
we did not see a relationship between changes in plasma
triglyceride concentrations and changes in inﬂammatory
markers or glycative stress. This outcome differs from the
ﬁndings of Nappo et al. who showed that post-meal triglyceride
change is related to changes in interleukin-6 and TNF-a [4].
Possible explanations for the difference between our study vs.
that of Nappo et al. include the amount of fat consumed (39 vs.
50 g), the type of fat consumed, the duration of diabetes (11–13
years vs. newly diagnosed) and the type of correlation analysis
used (area under the curve over 8 hvs.presumed individualtime
points). Another study, also using a standard commercial meal,
reported no correlation between changes in post-meal
triglycerides and those of hsCRP and IL-6 [16].
Apossiblelimitationofthisstudyistheagedifferencebetween
thetreatmentgroups,whichcouldcontributetothedifferencesin
biomarker changes. This is unlikely, however, because of the
relativelysmalldifferenceinagebetweenthetwogroupsandour
correction by statistical adjustment for age in the regression and
correlationanalyses.Otherfactorsknowntoaffectinﬂammatory
markers(gender,durationofdiabetesortreatment,lipid-altering
and anti-hypertensive medications) were similar in both insulin
treatment groups. The two groups also did not differ in weight
before randomization, nor did either group show signiﬁcant
weight gain during the 24 weeks in this sub-study. It is unlikely
that differences between the two groups in HbA1c at 24 weeks
inﬂuenced the acute response in inﬂammatory biomarkers,
because both groups had good overall glycaemic control
[HbA1c of 46 vs. 52 mmol⁄mol (6.4 vs. 6.9%)]. Similarly, we
do not believe that fasting blood glucose differences (8.2 vs.
6.3 mmol⁄l) inﬂuenced the acute response. Esposito et al.
reported that changes in hsCRP and IL-6 correlated with
changes in 2-h post-meal glucose and not with fasting plasma
glucose or HbA1c [8], and Festa et al. also reported that CRP is
more strongly related to post-load oral glucose tolerance testing
than to fasting glucose in subjects without diabetes [22]. In the
current study, statistical adjustments were also made for fasting
plasma glucose or insulin and HbA1c, age, gender and BMI
covariates in all of the regression and correlation analyses to
assure that the reported correlations were independent of these
factors.
The intent of this study was to compare biomarker responses
to a mixed-meal breakfast after 24 weeks of treatment with two
insulin regimens and to test the hypothesis that controlling post-
meal hyperglycaemia with prandial + basal insulin attenuates
the meal-induced increases in hsCRP, interleukin-6, TNF-a,
methylglyoxal and 3-deoxyglucosone more than basal insulin in
patients with Type 2 diabetes. The test meal before
randomization was performed to ensure the two groups were
similar in their post-meal responses at baseline, while the test
mealafter24 weeksoftreatmentwasperformedtotestthestudy
hypothesis.
In summary, our study shows that controlling post-meal
hyperglycaemia with prandial + basal insulin attenuates the
meal-induced increases in hsCRP, TNF-a and interleukin-6
comparedwithbasalinsulinoncedaily,bothplusmetformin.We
also demonstrated that post-meal changes in hsCRP, TNF-a,
interleukin-6, methylglyoxal and 3-deoxyglucosone levels are
signiﬁcantly correlated with post-meal glucose. As people
consuming three meals daily are in the postprandial state for
most of the 24 h, these ﬁndings suggest that controlling post-
meal glucose can potentially have a beneﬁcial effect on
cardiovascular events in patients with Type 2 diabetes.
Cardiovascular outcome studies where post-meal hyper-
glycaemia and meal-induced inﬂammation are reduced over a
longer time period are needed to prove that these changes can
decrease vascular disease in patients with Type 2 diabetes.
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